<unk>  (GvT) appears after allogeneic hematopoietic stem cell transplantation (HSCT). The<unk>  contains donor T cells (T lymphocytes) that can be beneficial for the recipient by eliminating residual malignant cells. GvT might develop after recognizing<unk> -specific or recipient-specific alloantigens. It could lead to remission or immune control of hematologic malignancies. This<unk>  applies in myeloma and lymphoid leukemias, lymphoma, multiple myeloma and possibly breast cancer. It is closely linked with<unk><unk> -host disease (GvHD), as the underlying principle of alloimmunity is the same. CD4+CD25+ regulatory T cells (Treg) can be used to suppress GvHD without loss of beneficial GvT<unk> . The biology of GvT response still isn't fully understood but it is probable that the reaction with polymorphic minor histocompatibility antigens expressed either specifically on hematopoietic cells or more widely on a number of tissue cells or<unk> -associated antigens is involved. This response is mediated largely by cytotoxic T lymphocytes (CTL) but it can be employed by natural killers (NK cells) as separate<unk> ors, particularly in T-cell-depleted HLA-haploidentical HSCT. __TOC__
Graft-versus-tumor effect
Immune privilege
Antineoplastic resistance
Late effect
Tissue selectivity
Cancer selection
Reverse tolerance
Central tolerance